To determine the optimal time for a second HIV-1 nucleic acid amplification assay to detect late postnatal transmission of HIV-1 (first negative test at 4-8 weeks of age) in resource-limited settings.
Introduction
HIV-1 serology cannot be used to diagnose perinatal HIV-1 infection among children under 18 months born to HIV-1infected women due to the presence of maternal, HIV-1specific antibodies, which cross the placenta during gestation. Infants in resource-rich settings are tested repeatedly to establish their HIV infection status during the first few weeks and months of life using PCR-based assays that detect either proviral HIV DNA or viral RNA in blood. However, in resource-limited settings, repeated PCR testing is usually not possible due to budgetary and infrastructure constraints. Routine PCR testing at 4-8 weeks of age, which detects 95-99% of in utero and peripartum infections [1] [2] [3] , may be feasible because it coincides with scheduled visits in many national health plans.
However, if an infant is breastfed, the risk of transmission continues. In resource-limited settings, clinicians commonly wait until 15-18 months of age, when complete cessation of breastfeeding has frequently occurred, to conduct HIV-1 diagnostic testing using a less expensive and more accessible antibody test. Relying on serological testing at 15-18 months delays life-saving initiation of antiretroviral therapy (ART) [4] , and the infant may die or become lost to clinical care prior to 15-18 months of age. Early infection has been associated with increased mortality [5] [6] [7] [8] [9] [10] [11] [12] [13] . Therefore, determination of a single additional HIV testing time point for children after 4-8 weeks of age would have great practical value for global HIV/AIDS programmes and could provide a costeffective method for infant HIV-1 diagnosis.
Using data from the HIV Prevention Trials Network (HPTN) 024 trial, we estimated the proportion of HIV-1infected infants who were still alive (and therefore who could have ART initiated) if they were tested at one of a set of time points. We sought to establish an optimal visit time for a second HIV-1 virologic test after 4-8 weeks of age to detect late postnatal transmission (transmission between 4-8 weeks and 1 year) in breastfed infants. Our definition of the optimal time for HIV-1 testing after 4-8 weeks was when the majority of infants who were infected in the late postnatal period would be captured. If there were no deaths due to HIV-1 infection, this visit could be when the child had completely weaned. However, because HIV-1-related deaths often occur prior to this [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , the optimal visit time we propose represents a window period late enough that most HIV-1 infections have occurred, but early enough that few of these HIV-1 infected infants have died.
Materials and methods

Patient population
We analyzed data from patients enrolled in HPTN 024. This was a multisite, double-blinded, placebo-controlled randomized trial of antibiotics to prevent chorioamnionitis-associated mother-to-child transmission (MTCT) of HIV-1 and preterm birth [14] . All mothers and infants received single dose nevirapine prophylaxis following the HIV Network for Prevention Trials (HIVNET) 012 protocol [15] . Infants underwent HIV-1 diagnostic testing using HIV-1 RNA assays at birth, at 4-8 weeks, and at 3, 6, 9, and 12 months of age. Of the four sites in HPTN 024, one counseled women to wean at 6 months (Dar es Salaam, Tanzania), and these data were not used in the analysis. Data from the three other sites in Lilongwe and Blantyre, Malawi, and Lusaka, Zambia, were analyzed. Breastfeeding duration at these three sites was similar with 93-97% still breastfeeding at 6 months, 86-93% at 9 months and 77-87% at 12 months with details previously published [16] .
Statistical methods
In the model, we define s to be the imprecisely measured time an infant would first test positive for HIV-1 and u to be the time of death. Because s is only known within an interval (e.g. some time between the last negative and the first positive PCR result), we used a multiple imputation procedure specifically designed for MTCTof HIV-1 [17] . Briefly, the imputation procedure was implemented 10 times resulting in 10 data sets with imputed values for s when the event time was interval or right censored. The analysis was run on each of the data sets. Rubin's rules [18] for combining results from imputed data analyses were used to obtain the final results.
We estimated the optimal visit time as follows: The variables t 1 ,. . .,t J denote the times of the J visits under consideration for HIV-1 testing beyond 4-8 weeks. At the jth, j ¼ 1,. . .,J, visit, occurring at t j , the number of infants who are alive and would test positive is denoted by n j (the total number of infants with s t j and u > t j ), which follows a binomial distribution with mean p j Â m in which m is the total number of infants who acquired HIV-1 infection through late postnatal transmission and p j probability of being alive and testing positive at t j conditional on acquiring HIV-1 infection through late postnatal transmission. An unbiased estimate of p j is given by n j /m. We defined the optimal visit time as the visit for which p j is greatest. Figure 1 illustrates an example of this procedure using hypothetical data with the same visit structure as HPTN 024. In this example, patients 1 and 6 are not included because their HIV-1 infection was detected at the 4-8week visit. There are J ¼ 4 visit times. Of the m ¼ 7 infants who test positive for HIV-1 infection within the first year, four (57%) are positive and alive at t 1 ¼ 3 months (patients 2-4, and 9). Therefore, if testing occurred at that point, only 57% of the infections would be detected. At t 2 ¼ 6 months, patients 2, 3, 5, 8, and 9 (71%) would be infected and detected. However, at t 3 ¼ 9 and t 4 ¼ 12 months, just four of the seven ( p 3 ¼ p 4 ¼ 57%) infections would be detected. Because the largest p j is p 2 , this hypothetical example indicates that 6 months would be the optimal additional testing point. To determine the proportion of infants who would be captured if testing was only performed at 6 weeks and 3, 6, 9 or 12 months, we used a similar procedure as above with n j equaling the number of infants who would first test positive at 6 weeks or the jth month and m equaling the total number of infants infected before their first birthday (including cases of in-utero and intrapartum infection).
Because duration of breastfeeding could influence the results, we also performed an alternate analysis that defined infant-specific testing times at 1 month after weaning or at 1 year of age, whichever comes first. The procedure for calculating the proportion detected under this algorithm is identical to the one described above except for adding a t j that varies over infants.
Results
Of 1671 infants born to HIV-1-infected women enrolled in HPTN 024 at the three African sites, 1609 (96.3%) had at least one HIV-1 diagnostic test. Figure 2 T À and T þ indicate tests were done at that time and the results were positive or negative, respectively. The dashed line represents the time a patient was followed to some unseen time when we would first be able to detect HIV infection (þ). When the line is highlighted, our calculations include the patient in the denominator. When the line is solid, the patient is included in the numerator. In this example, there are seven infants who would be included in the analysis. 
Discussion
Natural history studies have shown that 10-20% and 35-40% of untreated, HIV-1-infected children in resource-rich and resource-poor settings, respectively, die by 2 years of age [5] [6] [7] [8] [9] [10] [11] [12] [13] . Several reports have indicated that early HIV-1 infection in infants is associated with early mortality [11, 12] . Early identification of HIV-1 infection and initiation of appropriate treatment can delay disease progression significantly [4] . Thus, diagnostic testing of all HIV-exposed infants should be performed at a younger age (by 4-8 weeks of age), coincident with a routine infant vaccination visit, if possible. Such testing will identify those infants infected in utero, peripartum, and by early transmission through breast milk. Overall, in HPTN 024, 78% of all patients of HIV-1 transmission were detected at 6 weeks of age [16] . The remaining 22% of infected infants were infected during the late postnatal period. This is similar to other studies [15, [19] [20] [21] [22] [23] [24] [25] .
Our results indicate that, among breastfeeding HIV-1exposed infants, HIV-1 diagnostic testing using a virologic assay should be performed at 4-8 weeks of age to capture early HIV-1 transmission, and at the start of 1 month after weaning or 12 months of age to capture late postnatal transmission. This does not preclude additional HIV-1 testing in symptomatic infants or testing 1 month after the complete cessation of breastfeeding, if breastfeeding continues after 12 months. Incorporation of HIV-1 antibody assays beginning at 12 months of age may also be of benefit as a negative result could be definitive among non-breastfeeding infants and may thus reduce the number of virologic assays that need to be performed [26] .
Although these results suggest testing at 1 month postweaning, this may not in fact be realistic in many resource-poor settings in which caretakers must travel long distances for clinical care. Many caretakers may instead wish to wait until a scheduled clinic visit instead of making an extra trip to the clinic. In this case, our results suggest the testing at the 9-or 12-month visit is also an adequate approach, resulting in roughly the same proportion of infections detected.
These results were obtained using data from HPTN 024 in which single-dose nevirapine given to the mother during labor and to the infant shortly after birth was used for prevention of MTCT of HIV-1 [14, 15] . If other interventions to prevent MTCT of HIV-1 are used, such as prolonged prophylactic treatment of the infant with nevirapine, or HAART to the lactating mother, the optimal timing for diagnostic testing, and the most sensitive virologic test used (HIV-1 DNA vs. HIV-1 RNA) may be different. As described above, duration of breastfeeding also would make a difference in the optimal timing of a second test. For instance, in HPTN 024, mothers at one site stopped breastfeeding at 6 months. In this case, the optimal timing for a second test would presumably be a combination of 1 month after weaning and between 6 and 9 months. Exclusive breastfeeding was not recommended in HPTN 024, which was conducted before the benefits of exclusive breastfeeding were widely accepted. We did not capture data on breastfeeding practices such as mixed or exclusive breastfeeding that may have affected transmission rates and potentially change the optimal time for a second HIV diagnostic test. With these caveats in mind, the model used in this study to estimate the most efficient and cost-effective timing of a second diagnostic test should prove useful with regard to other strategies for the prevention of MTCT in resourcelimited settings.
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